Baricitinib treatment resolves lower airway inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques [scRNA-Seq] - - GEO DataSets

Summary

Format

Summary
Summary (text)
Unique Identifier List

Send to:

Choose Destination

File
Clipboard
Collections

Links from BioProject

Baricitinib treatment resolves lower airway inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques [scRNA-Seq]

(Submitter supplied) SARS-CoV-2 induced hypercytokinemia and inflammation are critically associated with COVID-19 disease severity. Baricitinib, a clinically approved JAK1/2 inhibitor, is currently being investigated in COVID-19 clinical trials. Here, we investigated the immunologic and virologic efficacy of baricitinib in a rhesus macaque model of SARS-CoV-2 infection. Viral shedding measured from nasal and throat swabs, bronchoalveolar lavages and tissues was not reduced with baricitinib. more...

Organism:: Macaca mulatta

Type:: Expression profiling by high throughput sequencing

Platform:: GPL27943
10 Samples

Download data: CSV

Series

Accession:: GSE159212

ID:: 200159212

PubMed Full text in PMC Similar studies SRA Run Selector

Supplemental Content

GEO DataSets

Functional Genomics Studies

Result Filters

Send to:

Links from BioProject

Supplemental Content

Related information

Important Links

Recent activity